We think that everyone should have access to affordable high quality healthcare.
Our vision is to enable cost-effective precision medicine by digitalizing and connecting existing data flows related to medication analysis.
Healthcare systems struggle to keep up with the financial challenge of a growing elderly population living longer, with at least one chronic disorder, combined with increasingly expensive new medication therapies.
There is an urgent need to do more with less. To improve outcomes for more people at a lower cost.
We support our partners in achieving this by enabling data-driven rational medication therapies.
Founder & CEO
Successful international CEO and serial entrepreneur with more than 20 years management experience and 5 years’ experience in the European health care and pharmacy industry. Co-founded essDOCS, which today is the world’s largest electronic bill of lading network. Before founding Apoteka, he restructured, raised new capital and managed a successful turnaround of Paranova Group, the second largest parallel distributor of medicine in the Nordics. Prior career include A.P. Møller Maersk, McKinsey & Company. Martin has a HD in Finance and an MBA in Finance & Entrepreneurship from The Wharton School at University of Pennsylvania.
Director of R&D
Responsible for the development of the back-end database and web services. Stefan is a an experienced developer and solutions architect with a background as Head of IT for Sundhedsdoktor.dk, a successful B2B healthcare platform and a career including Aller, Søndagsavisen and Retsmedicinsk institut. Stefan is educated as software engineer (Cand. Scient. Datalogi) from University of Copenhagen.
Anissa is responsible for product development, testing and implementation of pharmaceutical services. Anissa has a background as quality manager and lead pharmacist in Danish Pharmacies. She is specialized in medication therapy reviews (MTM) and LEAN design and implementation. Anissa is educated Cand. Pharm. at the Danish University of Pharamceutical Sciences.